|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
110,820,000 |
Market
Cap: |
1.29(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2859 - $11.99 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
5 |
Total Shares Sold |
0 |
349,251 |
362,612 |
450,033 |
Total Sell Value |
$0 |
$131,651 |
$141,672 |
$224,038 |
Total People Sold |
0 |
4 |
4 |
4 |
Total Sell Transactions |
0 |
6 |
7 |
12 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Smith J. Jefferson |
Chief Research Officer |
|
2024-01-23 |
4 |
S |
$0.37 |
$10,360 |
D/D |
(28,000) |
1,987,269 |
|
-3,078% |
|
Scimeca Dario |
General Counsel and Secretary |
|
2024-01-22 |
4 |
AS |
$0.36 |
$7,663 |
D/D |
(21,287) |
151,028 |
|
3,019% |
|
Amoroso Michael |
President and CEO |
|
2024-01-22 |
4 |
AS |
$0.36 |
$49,460 |
D/D |
(137,390) |
356,433 |
|
3,019% |
|
List Alan |
Chief Medical Officer |
|
2024-01-22 |
4 |
AS |
$0.36 |
$7,749 |
D/D |
(21,526) |
94,982 |
|
3,019% |
|
Scimeca Dario |
General Counsel and Secretary |
|
2024-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,345 |
172,315 |
|
- |
|
Amoroso Michael |
President and CEO |
|
2024-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
266,720 |
493,823 |
|
- |
|
Smith J. Jefferson |
Chief Research Officer |
|
2024-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,015 |
2,015,269 |
|
- |
|
List Alan |
Chief Medical Officer |
|
2024-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,012 |
116,508 |
|
- |
|
Kelly John Alexander |
Chief Financial Officer |
|
2024-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
116,690 |
614,169 |
|
- |
|
Amoroso Michael |
President and CEO |
|
2023-11-03 |
4 |
AS |
$0.40 |
$50,010 |
D/D |
(125,025) |
227,103 |
|
2,626% |
|
Scimeca Dario |
General Counsel and Secretary |
|
2023-11-03 |
4 |
AS |
$0.40 |
$6,409 |
D/D |
(16,023) |
112,970 |
|
2,626% |
|
Amoroso Michael |
President and CEO |
|
2023-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
283,390 |
352,128 |
|
- |
|
Scimeca Dario |
General Counsel and Secretary |
|
2023-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
55,077 |
128,993 |
|
- |
|
Kelly John Alexander |
Chief Financial Officer |
|
2023-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
108,188 |
497,479 |
|
- |
|
Scimeca Dario |
General Counsel and Secretary |
|
2023-08-31 |
4 |
A |
$0.39 |
$2,123 |
D/D |
5,443 |
73,916 |
|
- |
|
Smith J. Jefferson |
Chief Research Officer |
|
2023-08-31 |
4 |
A |
$0.39 |
$2,018 |
D/D |
5,175 |
1,940,254 |
|
- |
|
Kelly John Alexander |
Chief Financial Officer |
|
2023-08-31 |
4 |
A |
$0.39 |
$2,321 |
D/D |
5,951 |
389,291 |
|
- |
|
Kelly John Alexander |
Chief Financial Officer |
|
2023-08-18 |
4/A |
B |
$0.48 |
$43,200 |
D/D |
90,000 |
383,340 |
2.74 |
- |
|
Kelly John Alexander |
Chief Financial Officer |
|
2023-08-18 |
4 |
A |
$0.48 |
$43,200 |
D/D |
90,000 |
383,340 |
|
- |
|
Scimeca Dario |
General Counsel and Secretary |
|
2023-06-08 |
4 |
AS |
$0.75 |
$10,021 |
D/D |
(13,361) |
68,473 |
|
-59% |
|
Barton Shane |
VP & Corporate Controller |
|
2023-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,060 |
27,502 |
|
- |
|
Scimeca Dario |
General Counsel and Secretary |
|
2023-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,771 |
81,834 |
|
- |
|
Kelly John Alexander |
Chief Financial Officer |
|
2023-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,726 |
293,340 |
|
- |
|
Smith J. Jefferson |
Chief Research Officer |
|
2023-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,872 |
1,935,079 |
|
- |
|
List Alan |
Chief Medical Officer |
|
2023-04-27 |
4 |
AS |
$0.79 |
$6,139 |
D/D |
(7,771) |
56,496 |
|
-46% |
|
156 Records found
|
|
Page 1 of 7 |
|
|